374 related articles for article (PubMed ID: 33882244)
21. CT-based non-invasive identification of the most common gene mutation status in patients with non-small cell lung cancer.
Chen Z; Gao S; Ding C; Luo T; Xu J; Xu S; Li S
Med Phys; 2024 Mar; 51(3):1872-1882. PubMed ID: 37706584
[TBL] [Abstract][Full Text] [Related]
22. Current status and quality of radiomic studies for predicting immunotherapy response and outcome in patients with non-small cell lung cancer: a systematic review and meta-analysis.
Chen Q; Zhang L; Mo X; You J; Chen L; Fang J; Wang F; Jin Z; Zhang B; Zhang S
Eur J Nucl Med Mol Imaging; 2021 Dec; 49(1):345-360. PubMed ID: 34402924
[TBL] [Abstract][Full Text] [Related]
23. Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non-Small Cell Lung Cancer.
Yip SS; Kim J; Coroller TP; Parmar C; Velazquez ER; Huynh E; Mak RH; Aerts HJ
J Nucl Med; 2017 Apr; 58(4):569-576. PubMed ID: 27688480
[TBL] [Abstract][Full Text] [Related]
24. Can CT radiomic analysis in NSCLC predict histology and EGFR mutation status?
Digumarthy SR; Padole AM; Gullo RL; Sequist LV; Kalra MK
Medicine (Baltimore); 2019 Jan; 98(1):e13963. PubMed ID: 30608433
[TBL] [Abstract][Full Text] [Related]
25. A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management.
Sun X; Xiao Z; Chen G; Han Z; Liu Y; Zhang C; Sun Y; Song Y; Wang K; Fang F; Wang X; Lin Y; Xu L; Shao L; Li J; Cheng Z; Gambhir SS; Shen B
Sci Transl Med; 2018 Mar; 10(431):. PubMed ID: 29515002
[TBL] [Abstract][Full Text] [Related]
26. Can
Du B; Wang S; Cui Y; Liu G; Li X; Li Y
BMJ Open; 2021 Jun; 11(6):e044313. PubMed ID: 34103313
[TBL] [Abstract][Full Text] [Related]
27. Applications of radiomics-based analysis pipeline for predicting epidermal growth factor receptor mutation status.
Liu Z; Zhang T; Lin L; Long F; Guo H; Han L
Biomed Eng Online; 2023 Feb; 22(1):17. PubMed ID: 36810090
[TBL] [Abstract][Full Text] [Related]
28. Predictive value of multiple metabolic and heterogeneity parameters of
Shi A; Wang J; Wang Y; Guo G; Fan C; Liu J
Ann Nucl Med; 2022 Apr; 36(4):393-400. PubMed ID: 35084711
[TBL] [Abstract][Full Text] [Related]
29. Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.
Caicedo C; Garcia-Velloso MJ; Lozano MD; Labiano T; Vigil Diaz C; Lopez-Picazo JM; Gurpide A; Zulueta JJ; Richter Echevarria JA; Perez Gracia JL
Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2058-65. PubMed ID: 24990403
[TBL] [Abstract][Full Text] [Related]
30. Prediction of disease-free survival by the PET/CT radiomic signature in non-small cell lung cancer patients undergoing surgery.
Kirienko M; Cozzi L; Antunovic L; Lozza L; Fogliata A; Voulaz E; Rossi A; Chiti A; Sollini M
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):207-217. PubMed ID: 28944403
[TBL] [Abstract][Full Text] [Related]
31. Deep learning-radiomics integrated noninvasive detection of epidermal growth factor receptor mutations in non-small cell lung cancer patients.
Kim S; Lim JH; Kim CH; Roh J; You S; Choi JS; Lim JH; Kim L; Chang JW; Park D; Lee MW; Kim S; Heo J
Sci Rep; 2024 Jan; 14(1):922. PubMed ID: 38195717
[TBL] [Abstract][Full Text] [Related]
32. Clinical and radiological predictors of epidermal growth factor receptor mutation in nonsmall cell lung cancer.
Dang Y; Wang R; Qian K; Lu J; Zhang H; Zhang Y
J Appl Clin Med Phys; 2021 Jan; 22(1):271-280. PubMed ID: 33314737
[TBL] [Abstract][Full Text] [Related]
33. Efficient 18F-fluorodeoxyglucose positron emission tomography/computed tomography-based machine learning model for predicting epidermal growth factor receptor mutations in non-small cell lung cancer.
Ruan D; Fang J; Teng X
Q J Nucl Med Mol Imaging; 2024 Mar; 68(1):70-83. PubMed ID: 35420272
[TBL] [Abstract][Full Text] [Related]
34. Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer.
Mak RH; Digumarthy SR; Muzikansky A; Engelman JA; Shepard JA; Choi NC; Sequist LV
Oncologist; 2011; 16(3):319-26. PubMed ID: 21339258
[TBL] [Abstract][Full Text] [Related]
35. CT radiomics-based model for predicting TMB and immunotherapy response in non-small cell lung cancer.
Wang J; Wang J; Huang X; Zhou Y; Qi J; Sun X; Nie J; Hu Z; Wang S; Hong B; Wang H
BMC Med Imaging; 2024 Feb; 24(1):45. PubMed ID: 38360550
[TBL] [Abstract][Full Text] [Related]
36. 18F-FDG uptake for prediction EGFR mutation status in non-small cell lung cancer.
Guan J; Xiao NJ; Chen M; Zhou WL; Zhang YW; Wang S; Dai YM; Li L; Zhang Y; Li QY; Li XZ; Yang M; Wu HB; Chen LH; Liu LY
Medicine (Baltimore); 2016 Jul; 95(30):e4421. PubMed ID: 27472739
[TBL] [Abstract][Full Text] [Related]
37. Role of intratumoral and peritumoral CT radiomics for the prediction of EGFR gene mutation in primary lung cancer.
Yamazaki M; Yagi T; Tominaga M; Minato K; Ishikawa H
Br J Radiol; 2022 Dec; 95(1140):20220374. PubMed ID: 36115683
[TBL] [Abstract][Full Text] [Related]
38. Exploring Tumor Dissemination Characteristics and Prognostic Factors in Non-small Cell Lung Cancer: Insights From EGFR Mutations and PET/CT Radiomics.
Hsu CX; Yen SH
Acad Radiol; 2024 Mar; 31(3):1223-1224. PubMed ID: 37838524
[No Abstract] [Full Text] [Related]
39. The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer.
Liu A; Han A; Zhu H; Ma L; Huang Y; Li M; Jin F; Yang Q; Yu J
Oncotarget; 2017 May; 8(20):33736-33744. PubMed ID: 28422710
[TBL] [Abstract][Full Text] [Related]
40. CT and clinical characteristics that predict risk of EGFR mutation in non-small cell lung cancer: a systematic review and meta-analysis.
Zhang H; Cai W; Wang Y; Liao M; Tian S
Int J Clin Oncol; 2019 Jun; 24(6):649-659. PubMed ID: 30835006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
